PDGFRB and non-small cell lung carcinoma: For example, Allotinib can effectively inhibit VEGFR, PDGFR, FGFR, c-Kit and other signaling pathways, so it has multiple effects of anti-tumor angiogenesis and inhibition of tumor growth, showing good clinical effects in the treatment of NSCLC.